This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 28 March-3 April 2026 and includes updates on SARS-CoV-2 variant classification, Middle East respiratory syndrome coronavirus (MERS-CoV), cholera, HIV, and avian influenza.
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 21–27 March 2026 and includes updates on respiratory virus epidemiology in the EU/EEA, chikungunya, dengue, avian influenza, invasive meningococcal disease, aedes aegypti detection in Luxembourg, and measles.
Most respiratory viruses are declining across the EU/EEA: Influenza circulation and hospitalisations are decreasing. SARS CoV 2 activity is low. RSV activity remains elevated, with children under five years the most affected.
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 14 -20 March 2026 and includes updates on respiratory virus epidemiology in the EU/EEA, mass gathering monitoring, avian influenza, dengue, serious adverse events to IXCHIQ chikungunya virus disease vaccine, and invasive meningococcal disease.
Respiratory virus trends across the EU/EEA continue to show early signs of decline. RSV circulation remains high, with children under five years the most affected. Influenza circulation and hospitalisations are decreasing. SARS CoV 2 activity remains low.
Respiratory virus trends across the EU/EEA continue to show early signs of decline. RSV circulation remains high, with children under five most affected. Influenza circulation and hospitalisations are decreasing. SARS CoV 2 activity remains low.
This Reporting Protocol describes data collection for influenza, COVID-19, and other respiratory viruses (such as RSV or new viruses of public health concern) in the EU/EEA and wider WHO European Region. Data collection is integrated for most datasets in line with the operational considerations for respiratory virus surveillance in Europe.
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 28 February–6 March 2026 and includes updates on respiratory virus epidemiology in the EU/EEA, Sars-CoV-2 variant classification, MERS, mass gathering monitoring, and chikungunya.